Literature DB >> 12050481

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Charles Huggins, Clarence V Hodges.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12050481     DOI： 10.1016/s0022-5347(05)64820-3

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  616 in total

1.  Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate.

Authors:  Seetha Venkateswaran; David Margel; Stanley Yap; Karen Hersey; Paul Yip; Neil Eric Fleshner
Journal:  Can Urol Assoc J       Date:  2012-06       Impact factor: 1.862

2.  A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Authors:  Sara Lindström; Jing Ma; David Altshuler; Edward Giovannucci; Elio Riboli; Demetrius Albanes; Naomi E Allen; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Stephen J Chanock; Alison M Dunning; Heather Spencer Feigelson; J Michael Gaziano; Christopher A Haiman; Richard B Hayes; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Loic Le Marchand; Carmen Martínez; Kim Overvad; Afshan Siddiq; Meir Stampfer; Pär Stattin; Daniel O Stram; Michael J Thun; Dimitrios Trichopoulos; Rosario Tumino; Jarmo Virtamo; Stephanie J Weinstein; Meredith Yeager; Peter Kraft; Matthew L Freedman
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

Review 3.  Value of endocrine therapy for early and locally advanced prostate cancer.

Authors:  Manfred P Wirth; Michael Froehner
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 4.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

5.  Metabolic Changes in Androgen-Deprived Nondiabetic Men With Prostate Cancer Are Not Mediated by Cytokines or aP2.

Authors:  Thiago Gagliano-Jucá; M Furkan Burak; Karol M Pencina; Zhuoying Li; Robert R Edwards; Thomas G Travison; Shehzad Basaria
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

6.  Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial.

Authors:  Göksel Bayar; Hakan Şirin; Mustafa Aydın; Ayşim Özağarı; Orhan Tanrıverdi; Mustafa Kadıhasanoğlu; Muammer Kendirci
Journal:  Turk J Urol       Date:  2017-08-01

7.  Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?

Authors:  Jeanny B Aragon-Ching; William L Dahut
Journal:  Cancer Ther       Date:  2007

Review 8.  Concept and viability of androgen annihilation for advanced prostate cancer.

Authors:  James L Mohler
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

9.  Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model.

Authors:  Paulus Tsui; Marvin Rubenstein; Patrick Guinan
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

10.  Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer.

Authors:  P Henriksson; M Blombäck; G Bratt; O Edhag; A Eriksson; O Vesterqvist
Journal:  Med Oncol Tumor Pharmacother       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.